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Abbreviations 
5-HT  Serotonin 
8-OH-DPAT     8-hydroxy-2-(di-n-propylamino)-tetralin 
ANOVA         Analysis of variance 
BBB            Blood-brain barrier 
BCRP   Breast cancer resistant protein 
BPND   Binding potential 
CER  Cerebellum 
CNS    Central nervous system 
DRN   Dorsal raphe nucleus 
Emax  Maximum effect  
HIP  Hippocampus 
IP  Intraperitoneal administration 
IV  Intravenous administration 
Kd   Dissociation constant 
Ki   Inhibition constant  
Kp,brain   Brain-to-plasma concentration ratio 
MPFC   Medial prefrontal cortex 
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MPPF 2'-methoxyphenyl-(N-2'-pyridinyl)-p-fluoro-
benzamidoethylpiperazine 
OAB         Overactive bladder  
PD          Pharmacodynamics  
PET  Positron emission tomography 
P-gp   P-glycoprotein  
PK  Pharmacokinetics  
RO  Receptor occupancy  
ROI   Region of interest 
SCL   Superior colliculus lesion  
SD   Sprague-Dawley or Standard deviation 
SRTM   Simplified reference tissue model 
WAY-100635  N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2- 
   pyridinyl)cyclohexanecarboxamide 
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Summary 
Drug discovery and development is time consuming and a costly procedure. 
Considering the current high failure rate of drugs that enter clinical trials, there is a clear 
need for more efficient and sensitive strategies in the search for useful medicine. The 
challenges for the pharmaceutical industry range from the evaluation of potential new 
drug candidates, the determination of drug pharmacokinetics/pharmacodynamics, the 
measurement of biomarker response as a determinant of drug efficacy, and the 
pharmacological characterization of mechanisms of action. Positron emission 
tomography (PET) is a powerful quantitative imaging technique for looking at 
biochemical pathways, molecular interactions, drug pharmacokinetics and 
pharmacodynamics. In this thesis, I conducted the pharmacological characterization of a 
novel 5-HT1A antagonist, 1-{1-[2-(7-Methoxy-2,2-dimethyl-4-oxochroman-8-
yl)ethyl]piperidin-4-yl}-N-methyl-1H-indole-6-carboxamide fumarate (E2110) by using 
small-animal PET and assessed the potency of E2110 as an agent for treatment of OAB. 
First, PK-RO relationship of E2110 in rat was evaluated with specific tracer [11C]WAY-
100635. Subsequent PK/PD modeling and simulation was performed based on the 
obtained data to investigate RO data could be a useful pharmacological indices for 
understanding pharmacological efficacy in animal model. Moreover, the drug-target 
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interaction was investigated more directly using radiolabeled E2110 ([11C]E2110) by in 
vivo Scatchard analysis.  
Central 5-HT1A receptor occupancy was evaluated at different oral doses of 
E2110 and time points after treatment in rats. Time-radioactivity curves after 
administration of [11C]WAY-100635 were analyzed by simplified reference tissue model 
(SRTM) and binding potential based on specific binding compared to nondisplaceable 
uptake (BPND) were estimated. Obtained occupancy data were analyzed by “static” 
(simple Emax model) or “dynamic” (effect compartment model with plasma 
pharmacokinetic profile of E2110) approach. The plasma concentrations inducing 50% 
RO (EC50) estimated were in good agreement in both models. Also, the EC50 values did 
not markedly differ between MPFC and DRN. These findings indicate that E2110 has 
equal antagonist activities against pre- and post-synaptic 5-HT1A receptors. Meanwhile, 
these in vivo EC50 values were supposed to be comparable to the in vitro Ki value (0.045 
nM) take into account the free fraction in plasma and P-gp susceptibility of E2110. The 
estimated parameters were used to simulate RO profile in pharmacological model. 
Dose-dependent therapeutic effects of E2110 on dysregulated micturition in different rat 
models of pollakiuria were also consistently explained by achievement of 5-HT1A RO 
by E2110 in a certain range (≥ 60%). These findings support the possibility of PET RO 
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as a surrogate biomarker to evaluate the drug acting on 5-HT1A receptors and associate 
it with counteracting effect of E2110 on OAB. 
In addition, direct ligand-target interaction was investigated by using 
radiolabeled E2110. In vivo Scatchard analysis was performed under the transient 
equilibrium condition of specific binding of E2110. Under the condition that P-gp 
activity on BBB was intentionally inhibited by pretreatment of potent P-gp inhibitor, 
elacridar, the affinity of E2110 to the central 5-HT1A receptor was investigated. The 
regional differences of expression level of P-gp might affect to the estimation of binding 
affinity of E2110, the supposed free-based Kd value was close to that obtained by in 
vitro receptor binding assay.  
In summary, the use of PET in early drug discovery could provide the 
pharmacological information about the relationship between in vitro and in vivo for 
novel CNS drugs. Further PK/PD modeling and simulation approach using PET could 
be a powerful translational tool to bridge the gap between drug discovery in animals and 
drug development in human patient.  
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Background 
Increasing costs of drug development and reduced pipeline productivity have 
been growing concerns for new drug development in recent years. It has been estimated 
that the total discovery costs of a new medicine to the completion of phase 3 clinical 
trials can now take up to 15 years and cost up to $1.5BN [1]. In spite of that, historically, 
only 14% of the tested products entering Phase 1 trials eventually cleared the hurdle of 
gaining approval and entered the market. More than 50% of this attrition resulted from 
failure to demonstrate efficacy in phase 2 studies [2]. In particular, the success rate of 
drugs targeting disorders of the central nervous system (CNS) is half of the overall 
clinical approval success rate and the mean clinical-plus-approval phase time for U.S.- 
approved CNS drugs was 32 months or 35% longer than that for non-CNS drugs [3]. As 
a consequence, despite there is a significant unmet medical need for therapeutics, 
several pharmaceutical industries have decreased their investments for CNS drug 
discovery and development [4]. 
Many of these failures occur due to the lack of bridging activities in preclinical 
stage. To reduce the risk of failure caused by insufficient information about drug action 
and target molecule, the activities which bridge the gap between drug discovery in 
animals and drug development in human patients are required as translational research. 
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Translational research activities in pharmaceutical industry aim to predict the biomarker 
profiles or pharmacological effects in clinical situations based on in vitro or preclinical 
information. To conduct the translational drug research, understanding and learning the 
physiology and the mechanisms involved in drug distribution and drug-target interaction 
processes at a preclinical level are helpful to scale those processes to human [5].  
One of the most established approach in translational research is molecular 
imaging using Positron Emission Tomography (PET) [6]. PET is a non-invasive 
molecular imaging technique which provides functional information of physiological, 
biochemical and pharmacological processes in laboratory animals and humans [7−10]. 
Quantitative information from PET analysis enables us to monitor the change of target 
function by drug treatment.  Over the last fifteen years, the importance of imaging as a 
critical tool for drug development has been recognized. This has been enhanced by 
technological advances in the realm of small animal imaging that have demonstrated 
their potential as translational tools [11, 12]. Currently, molecular imaging is an essential 
tool for translational research and new drug development. 
Additionally, in recent years, pharmacokinetic/pharmacodynamic (PK/PD) 
modeling approaches in translational drug research are increasingly used to understand 
the relationship between drug concentration profiles and drug effects/target marker 
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profiles [13]. This methodology is applied in drug discovery and development areas such 
as the selection of drug candidates with the most favorable PK/PD properties and the 
prediction of exposure response in patients with the aim of optimizing the design of 
early clinical trials. The modeling of PK/PD relationships can be of great value in 
understanding drug action and finding a drug dosing regimen that results in optimal 
therapeutic outcome [14−18]. The use of PK/PD modeling relies on the prediction of the 
time course of drug action in patients using nonclinical information, because nonclinical 
studies are useful alternatives for investigating PK/PD relationships to get insight into 
the in vivo mechanism of drug action. The integration of PK/PD modeling and 
simulation has provided valuable opportunities for accelerating the evaluation of new 
chemical entities in the clinic and can in principle contribute to shortening the overall 
period of drug development process. Due to the extraordinary time and cost of drug 
development, it is highly desirable for pharmaceutical industries to have effective tools 
to confirm the action of selected compound for targets and target engagement for 
therapeutic indications. 
1-{1-[2-(7-Methoxy-2,2-dimethyl-4-oxochroman-8-yl)ethyl]piperidin-4-yl}-N-
methyl-1H-indole-6-carboxamide fumarate (E2110) is a novel compound with high 
selectivity and affinity to 5-HT1A receptors. In control of lower urinary tract function, 
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many pharmacological studies in animals have revealed that 5-HT receptor agonists or 
antagonists modulate reflex bladder and urethral sphincter activity [19−23]. Among them, 
it has been reported that 5-HT1A receptor antagonist is expected to improve symptoms 
associated with overactive bladder (OAB) [24, 25].  
This thesis highlights the significance of in vivo proof-of-
target/mechanism/efficacy studies to evaluate the potential of antagonist of 5-HT1A 
receptors to treat OAB. This PK/PD framework using small-animal PET would help to 
scale information from in vitro binding studies and preclinical receptor occupancy 
studies to predict human 5-HT1A RO and pharmacological efficacy. 
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Aims of This Study 
The purpose of this thesis study was to evaluate the utility of quantitative 
molecular imaging (e.g., receptor occupancy, in vivo receptor binding assay) using 
small-animal positron emission tomography for CNS drug discovery and development 
as a biomarker and to develop a translational pharmacokinetic and pharmacodynamic 
(PK/PD) modeling framework by integrating in vitro, and in vivo preclinical data with 
PK/PD models to predict the effects of drugs in humans. For this aim, occupancy of 5-
HT1A receptor by E2110 was quantified in living rat brains by a high-resolution PET 
system with a radioligand suitable for imaging of the target molecule. The obtained 
pharmacodynamic data were fitted by the pharmacokinetic data of E2110 with 
mathematical model. The constructed PK/PD (RO) model for E2110 was used as the 
tools to predict the target receptor occupancy of E2110 for the preclinical model for 
OAB. The in vitro-in vivo correlation of pharmacological activity of E2110 were 
discussed by both PK-RO relationship and in vivo Scatchard analysis using radiolabeled 
E2110. In accordance with the results of modeling and simulation of 5-HT1A receptor 
occupancy and pharmacological efficacy in animals, the required target occupancy level 
for the pharmacological effect was discussed.  
In the Chapter 1, the RO-plasma concentration profile and RO-time profile after 
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oral administration of E2110 to rats were investigated with [11C]WAY-100635, a 
specific radioligand for 5-HT1A receptor. Based on the results of PK-RO analysis, RO 
profiles in animal pharmacological model were projected. Pharmacological effect of 
E2110 on micturition in different rat models of pollakiuria was explained by the range 
of 5-HT1A RO achieved by E2110. 
In the Chapter 2, distribution and binding affinity in different brain regions were 
examined by means of PET with [11C]E2110. For the improvement of brain entry of 
[11C]E2110, elacridar was pretreated as P-gp inhibitor at BBB. Under this condition, 
various specific radioactivities of [11C]E2110 were injected. In vivo Scatchard analysis 
was performed based on the specific binding data at the point when transient 
equilibrium was established. Estimated binding affinity data (Kd) were compared with 
Ki value obtained by in vitro receptor binding assay and EC50 value in receptor 
occupancy study with [11C]WAY-100635 in Chapter 1. 
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Chapter. 1  
A Pharmacokinetic/Pharmacodynamic PET Study of Central 
Serotonin 1A Receptor Occupancy by A Potential Therapeutic 
Agent for Overactive Bladder 
 
§ 1 Introduction 
Overactive bladder (OAB) is a pathological condition symptomatically 
diagnosed based upon “a symptom developing urinary urgency with or without urge 
incontinence and usually developing frequent urination with no proven infection or 
other obvious pathological factors [26].”, and is one of the most common diseases in the 
elderly. Most OAB cases are idiopathic, and anticholinergic agents are frequently used 
for its treatment. However, it is difficult to maintain sufficient dosage of an 
anticholinergic agent for expected efficacy without causing significant adverse events, 
such as dry mouth, gastrointestinal disorder, and urinary retention, thereby limiting its 
use [27−29].  
Several central nervous system (CNS) transmitter systems, including adrenaline, 
noradrenaline, gamma-aminobutyric acid, opioids, dopamine, and glutamate 
transmissions are known to be involved in micturition control. Serotonin (5-HT) and its 
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receptors may also play an important role in the regulation of micturition reflex (Figure 
1). Pharmacological studies suggested that serotonin 1A (5-HT1A) receptor stimulation 
by administration of its agonist, 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), 
decreased the volume threshold for bladder contractions and facilitated voiding. On the 
other hand, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-
pyridinyl)cyclohexanecarboxamide (WAY-100635), a silent 5-HT1A receptor antagonist, 
increased residual bladder volume and thus markedly reduced voiding efficiency [30]. 
Compounds with higher selectivity for 5-HT1A receptors may therefore provide a 
significant option for the treatment of OAB.  
1-{1-[2-(7-Methoxy-2,2-dimethyl-4-oxochroman-8-yl)ethyl]piperidin-4-yl}-N-
methyl-1H-indole-6-carboxamide fumarate (E2110; Figure 2) is a novel compound with 
high selectivity and affinity for 5-HT1A receptors in the rodent brain in vitro. 
[35S]guanosine-5’-O-(3-thio)-triphosphate (GTPγS) binding studies have demonstrated 
that E2110 is a full antagonist of 5-HT1A receptors.  
As the occupancy of target receptors by a therapeutic agent is intimately 
correlated with the intensity of its pharmacological effects, measurements of receptor 
occupancy (RO) may offer an objective index for assessing pharmacokinetics (PK) and 
pharmacodynamics (PD) of such a drug or drug candidate. Positron emission 
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tomography (PET) has been recognized as an important tool in drug development, since 
it is capable of providing valuable information on PK, BBB penetration, and PD of a 
receptor ligand, as exemplified by RO, in living brains of diverse species including 
rodents and humans. Translation of target RO data from preclinical species to humans 
may be a viable strategy for predicting clinical efficacy and optimal dosage of a novel 
therapeutic agent, given that the relationship between RO and clinical effects has been 
established. 
This approach relies upon an understanding of the relationship between drug 
concentrations in plasma and CNS that results in a specific level of target occupancy. A 
PK/PD modeling approach has also been used to describe the relationship between drug 
concentrations and RO. A maximum effect (Emax) model to describe this relationship 
was typically applied to the PD assay, but such “static” approach could be of 
insufficient accuracy, particularly in case of distribution of the drug from plasma to 
brain or binding kinetics of the drug at the receptor being relatively slow. An optimal 
assessment requires determination of RO and plasma concentration at multiple time 
points postdose. Indirect or effect compartment models may be more appropriate than 
direct models to describe the relationship between occupancy and plasma concentration 
in treatment with a drug with delayed BBB penetration and/or target PD [31].  
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In the present study, I examined the utility of 5-HT1A receptor PET imaging for 
obtaining a surrogate marker for assessing therapeutic effects of E2110 on urinary 
bladder dysfunctions. Occupancy of central 5-HT1A receptors by E2110 was determined 
in rats using PET with a radiotracer, [11C]WAY-100635. A compartmental PK/PD 
modeling approach was then utilized to describe the relationship between plasma 
concentration of E2110 and 5-HT1A RO by E2110 in several regions of rat brains at 
different time points after its oral administration. The results have supported the 
preclinical use of PET in combination with analytical models to predict PK/PD of a 
drug in humans. 
 
§ 2 Materials and Methods 
Animals 
The research protocols of the present work were approved by the Animal 
Ethics Committee of the National Institute of Radiological Sciences and the Animal 
Ethics Committee of Eisai Co., Ltd. and were performed in accordance with the 
Principles of Laboratory Animal Care (NIH publication No. 85-23, revised 1985). 
Male and female Sprague-Dawley (SD) rats were purchased from Japan SLC 
(Hamamatsu, Japan) and Charles River Japan Inc. (Kanagawa, Japan). All rats were 
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kept in animal rooms maintained at 20−26°C and illuminated from 7 am to 7 pm daily, 
with ad libitum access to food and water. 
 
Reagents 
E2110 was synthesized at Eisai Co., Ltd. (Japan). WAY-100635 maleate, 5-HT 
and 8-OH-DPAT were from Sigma-Aldrich (St. Louis, MO, USA). [3H]2'-
methoxyphenyl-(N-2'-pyridinyl)-p-fluoro-benzamidoethyipiperazine ([3H]MPPF) was 
from PerkinElmer Life & Analytical Sciences (Boston, MA, USA). Tamsulosin 
hydrochloride was purchased from WAKO Pure Chemical Industries (Osaka, Japan). All 
other reagents and chemicals were of analytical grade, and were commercially available.  
 
Binding assay in rat hippocampal membrane fraction  
Rat hippocampal samples were weighed, homogenized in 10-fold volume of 50 
mM Tris-HCl (pH 7.4) on an ice bath, and centrifuged (50,000×g, 4°C, 20 min). The 
precipitate was further homogenized in a 10-fold volume of 50 mM Tris-HCl (pH 7.4) 
on an ice bath and centrifuged (50,000×g, 4°C, 20 min). The obtained precipitate was 
homogenized in 50 mM Tris-HCl (pH 7.4) to render a concentration of 100 mg tissue 
eq./mL. The obtained microsomal fraction was stored as a receptor stock solution at 
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−80°C until use. In saturation binding experiments, the suspension of hippocampal 
membranes (5 mg tissue eq./tube) in the tube was incubated with different 
concentrations (0.03−7.77 nM) of [3H]MPPF in a total 1 mL reaction volume at 25°C 
for 60 min. The reaction was terminated, and bound radioactivity was separated from 
free radioligands by filtering and washing three times with 3 mL of 50 mM Tris-HCl 
(pH 7.4). The radioactivity content of the filters in 5 mL of liquid scintillator 
(Atomlight; PerkinElmer) was counted by TR2500 scintillation counter (PerkinElmer 
Life & Analytical Sciences). The specific binding was determined as the difference 
between total and nonspecific binding, measured in the absence and presence of 100 μM 
5-HT. Data were analyzed by Scatchard plot to estimate equilibrium constant (Kd) 
values. For the competition experiments, binding assays were carried out using 0.3 nM 
[3H]MPPF in the presence of various concentrations of E2110 (0.01 to 10 nM) or WAY-
100635 (0.03 to 30 nM). The IC50 values for E2110 and WAY-100635 were corrected to 
the Ki values using the Kd values of [3H]MPPF according to the following equation: 
d
50
i
K
]dradioligan[
1
IC
K
+
=      (1) 
where [radioligand] means the concentration of the radioligand used. 
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Protein binding of E2110 in rat plasma 
The in vitro unbound fraction of E2110 in male SD rat plasma was quantified 
by equilibrium dialysis. One mL of the E2110 spiked sample (100, 1000 and 10000 
ng/mL) and phosphate buffered saline (PBS) were applied to one and the other 
chambers of a dialysis cell, respectively. The cartridge was incubated in a water bath for 
24 hr at 37°C. After incubation, aliquots were sampled from both chambers and 
submitted to determination of the concentration of E2110 in each matrix by liquid 
chromatography-tandem mass spectrometry. Unbound fractions for each compound 
were calculated as the ratio of E2110 concentration from the PBS side to that from the 
plasma side of the dialysis apparatus. 
 
Radioligand synthesis 
[11C]WAY-100635 was prepared by 11C-acylation of WAY-100634 with 
[11C]cyclohexanecarbonyl chloride as previously described in detail [32]. Semi-
preparative reverse-phase HPLC was used for the purification of [11C]WAY-100635. 
Radiochemical purity of the radioligand was more than 95%. Average specific 
radioactivity of [11C]WAY-100635 was 196.4 ± 83.4 GBq/mmol at the end of synthesis 
(EOS). All injections of [11C]WAY-100635 were given within 30 min after EOS. 
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PET data acquisition 
All PET scans for rats were performed with a small animal-dedicated 
microPET FOCUS 220 system (Siemens Medical Solutions USA, Knoxville, TN, USA), 
which yields a 25.8 cm (transaxial) × 7.6 cm (axial) field of view (FOV) and a spatial 
resolution of 1.3 mm full width at half maximum at the center of FOV [33]. The rats were 
anesthetized with 1.5−2% isoflurane in air (flow rate: 2 L/min). Their body temperature 
was controlled using homeothermic controller and plate with a rectal probe, and their 
heart rates and arterial oxygen saturations were continuously measured by a pulse 
oximeter (CANL-425SVA; Med Associates, St. Albans, VT, USA). Respiration rates of 
these animals were also monitored with a custom-made monitoring system (Nagano 
Electronics, Hitachinaka, Japan). A 20 min transmission scan for attenuation correction 
was performed using a spiraling 68Ge−68Ga point source. Subsequently, list-mode scans 
were carried out for 90 min. All list-mode data were sorted and Fourier rebinned into 
two-dimensional sinograms (frames: 4 × 1, 8 × 2, and 14 × 5 min). Images were 
thereafter reconstructed using two-dimensional filtered back-projection with a 0.5 mm 
Hanning filter. [11C]WAY-100635 was injected via the tail vein as a single bolus at the 
start of emission scanning. The injected dose of the radiotracer was 85.3 ± 28.6 MBq/rat 
(mean ± SD).  
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PET data analysis 
Anatomical regions of interest (ROIs) were placed on the medial prefrontal 
cortex (MPFC) and dorsal raphe nucleus (DRN) using PMOD® image software (PMOD 
Group, Zurich, Switzerland) with reference to the MRI template. Radioligand binding 
was examined by calculating the binding potential (BPND; ratio at equilibrium of 
specifically-bound radioligand to that of nondisplaceable radioligand in tissue) based on 
a simplified reference tissue model (SRTM) [34] using the cerebellar time-radioactivity 
curve as reference. Occupancy of 5-HT1A receptors by E2110 was calculated using the 
following equation: 
baseline,ND
drug,NDbaseline,ND
BP
BPBP
RO
−
=
 
    (2) 
where BPND, baseline and BPND, drug are estimated BPND at baseline and following drug 
administration, respectively. 
 
Rat RO study 
To examine the dose-RO relationship at a single time point, four male SD rats, 
which had undergone a baseline PET imaging in advance, were scanned with PET at 4 
hours after being pretreated with 4 oral doses (0.3, 1, 3, 10 mg/kg) of E2110. In this 
assay, approximately 250 μL of blood samples were collected from the tail vein upon 
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initiation of the scan for quantification of plasma concentration of E2110. Furthermore, 
RO at different time points after the drug administration was examined by conducting 
PET scans of four male SD rats at 2, 4, 6 or 8 hours after pretreatment with a single oral 
dose of 1 mg/kg E2110. In addition to this series of PET assays for male rats, pilot PET 
scans for female rats (n = 3) were carried out at baseline and 4 hours after oral 
administration of 0.1 mg/kg E2110 to examine whether relationships between plasma 
concentration of E2110 and RO by this drug in the brain are consistent between two 
genders. In all experiments, scans for the same individual receiving E2110 were 
conducted more than 1 week apart. 
 
PK study in rats 
E2110 was administered orally to male and female SD rats, (4 animals/sex) at a 
dose of 1 mg/kg. Blood samples were collected from the jugular veins by heparinized 
syringes at 0.25, 0.5, 1, 2, 4, 6, and 8 hours after dosing. 
 
Quantitative bioanalysis. 
Concentrations of E2110 were determined in plasma or PBS by liquid 
chromatography-tandem mass spectrometry. Samples (5 μL) were injected into an L-
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column ODS (35 × 2.1 mm; 5 μm, Chemical Evaluation and Research Institute, Tokyo, 
Japan) with a flow rate of 0.6 mL/min. 0.1% formic acid in water and acetonitrile were 
used as mobile phase A and B, respectively. The gradient elution started with a gradient 
from 0% to 100% mobile phase B for 2 min, then 1 min of 100% B, followed by a 
gradient of 100% to 0% for 0.01 min at the end, at a flow rate of 0.6 mL/min. The mass 
spectrometer (Quattro Ultima-Pt; Micromass, Waters Ltd., Manchester, UK) was 
operated in a positive ion multiple reaction monitoring mode. E2110 was monitored 
using mass transitions of 490.4/459.2. Tamsulosin was used as an internal standard, and 
was monitored using a mass transition of 409.3/200.0. The lower limit of quantification 
of E2110 in plasma was 0.5 ng/mL. 
 
PK/PD modeling 
1) Analysis of dose-RO relationships 
As described in previous studies on 5-HT1A receptor antagonists [35−37] the 
relationship between RO and plasma drug concentration at equilibrium can be described 
according to the law of mass action by the curvilinear function, based on the assumption 
that the free brain concentration is equal to free plasma concentration and the free 
fraction in plasma is not concentration-dependent: 
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p
p
app
d
max C
CK
RO(%)RO
+
=
 
   (3) 
where ROmax is the maximum occupancy that can be induced by E2110, Kdapp the 
apparent equilibrium constant, and Cp the plasma concentration of E2110. This model is 
analogous to the Emax model: 
p
p50
max C
CEC
EE
+
=
 
     (4) 
where Emax (ROmax) is the maximum effect (maximum RO) and EC50 (= Kd) is the 
E2110 plasma concentration required to produce 50% of Emax. EC50 can be converted to 
“free” based EC50 by multiplying the unbound fraction ratio in plasma. In this study, the 
relationship between E2110 plasma concentration and RO was characterized by fitting 
the Emax model to the experimental data. 
 
2) Time-course study 
The effect compartment model is illustrated in Figure 3. The mean plasma 
concentration profile of E2110 in each of four rats was fitted by two-compartment 
model with first order absorption and elimination. A sigmoid Emax model (Equation 4) 
based on the concentration in the effect compartment was fitted to the PD (RO) data. PK 
and PD models were linked using an effect compartment model [38] described by the 
following equation: 
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)CC(k
dt
dC
ep0e
e
−=      (5) 
where Cp and Ce are concentrations of E2110 in the plasma and effect compartments, 
respectively, and ke0 represents the equilibration rate constant for the effect 
compartment. PK and PD parameters were estimated by using SCIENTIST (Version 
2.01, MicroMath Research, UT, USA). 
 
Pharmacological tests 
Female SD rats were used for pharmacological assays to assess effects of 
E2110 on micturition functions, since insertion of a urinary catheter into the bladder 
could be readily performed in female rats. 
 
1) 5-HT1A receptor agonist-induced model of OAB 
Catheter implantations and cystometric investigations were performed based on 
the reported method [39]. Briefly, on the day before the cystometric experiment, female 
SD rats were initially anesthetized with pentobarbital (50 mg/kg, IP). Catheters were 
inserted into the femoral vein, the dome of the stomach and the dome of the bladder. In 
the cystometric study, the bladder catheter was connected to an infusion pump and a 
pressure transducer (DX-312; Nihon Kohden Co., Tokyo, Japan) by three-way stopcock. 
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Saline was infused into the bladder and femoral vein. After bladder pressure was 
stabilized, 8-OH-DPAT (0.06 mg/kg/hr) was infused into the femoral vein instead of 
saline. Bladder pressure was monitored with a pressure transducer and a pressure 
amplifier (AP-601G; Nihon Kohden), and recorded on a pen recorder (WT-645G; Nihon 
Kohden). The following three micturition intervals (i.e., intervals between consecutive 
peaks of bladder pressure induced at the time of bladder content evacuation) were 
obtained: (1) basal micturition interval (intervals before 8-OH-DPAT administration), 
(2) pre-administration micturition interval, (intervals immediately before administration 
of E2110 or vehicle), and (3) post-administration micturition interval (intervals 
observed between 1and 2 hr after administration of E2110 or vehicle). The change in the 
micturition interval after E2110 administration was used as an index of the efficacy of 
the treatment. E2110 (0.03, 0.1 or 0.3 mg/kg) or vehicle was administered to four 
groups of eight conscious rats orally. 
 
2) Superior colliculus lesion (SCL) model  
For lesioning of the brain to stimulate the micturition reflex, anesthesia was 
induced in female SD rats with 4% halothane and an N2O/O2 (2:1) gas mixture, it was 
maintained with 2% halothane, and each animal was mounted onto a stereotaxic 
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apparatus. The skull was then exposed, and holes were drilled for the superior collicular 
placement (anterior = + 2.0 mm; lateral = ±1.7 mm; horizontal = 0.0 mm) of a lesion 
electrode (TM-type tip; 0.7 mm × 1.5 mm). The bilateral superior colliculi were 
lesioned by electrical heating at 65°C for 4 min with a lesion generator (RFG-4; 
Muromachi Kikai Co., Ltd., Tokyo, Japan). Catheter implantations and cystometric 
investigations were performed with the same methodologies as in the 5-HT1A receptor 
agonist-induced model. E2110 (0.1, 0.3 or 1 mg/kg) or vehicle was administered to four 
groups of eight conscious rats orally. The three micturition intervals were obtained and 
drug-induced changes in the micturition intervals were evaluated. In this assay, the post-
administration micturition interval was defined as the average of the micturition 
intervals over an observation period between 0.5 and 1 hr after administration. 
 
Data presentation and statistical analysis 
Data are expressed as mean ± standard error of mean (S.E.M). In the 
pharmacological study, the statistical significance of differences between the vehicle- 
and E2110-treated groups was tested using one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparison test. A probability (p) value of < 0.05 (two-
sided) was considered statistically significant. All statistical analyses were performed 
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using the SAS software package version 8.1 or 8.2 (SAS Institute Japan Ltd., Tokyo, 
Japan). 
 
§ 3 Results 
Binding assay in rat hippocampal microsomal fraction 
The affinity of E2110 for rat 5-HT1A receptors was examined in brain tissues. 
[3H]MPPF bound to membrane preparations from the rat hippocampus with a Kd value 
of 0.92 nM. E2110 and WAY-100635 inhibited this [3H]MPPF binding in a 
concentration-dependent manner (Figure 4). Ki values of E2110 and WAY-100635 for 
rat 5-HT1A receptor were 0.045 nM (Table 1) and 0.121 nM, respectively. 
 
5-HT1A RO studies 
As MPFC and DRN represent brain areas enriched with post- and pre-synaptic 
5-HT1A receptors, respectively, ROIs were defined in these areas for subsequent 
analyses. As visually demonstrated by inhibition of [11C]WAY-100635 binding in 
representative PET images (Figure 5), E2110 dose-dependently induced 5-HT1A RO at 
single oral doses of 0.3, 1, 3, and 10 mg/kg in each region. The relationship between the 
plasma concentration of E2110 and its occupancy of 5-HT1A receptors could be 
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described by hyperbolic function (Equation 4, Figure 6). Since high doses of E2110 (3 
and 10 mg/kg) induced full occupancy of 5-HT1A receptors in both ROIs, Emax (ROmax) 
was fixed at 100%. By applying this Emax model, the E2110 plasma concentration 
required for 50% RO (EC50) was estimated to be 3.68 ng/mL (7.51 nM) and 2.64 ng/mL 
(5.40 nM) in MPFC and DRN, respectively (Table 1). 
 
Protein binding and PK in rat plasma 
The binding of E2110 to plasma proteins was not dependent on its 
concentration. The average percentage of protein-unbound E2110 in plasma was 6%. 
Male and female SD rats were given a single oral dose of E2110 (1 mg/kg). The time 
course of mean plasma concentrations was reasonably well described by a two-
compartment model with first-order absorption, as displayed in Figure 7. E2110 was 
rapidly absorbed following oral administration, with peak concentrations in plasma 
(Cmax) occurring within 1 hour after dosing in all groups of rats. Elimination of the drug 
from plasma occurred more slowly in females than in males. 
The PK parameters for E2110 derived from these data, consisting of half-life in 
plasma (t1/2), maximum concentration (Cmax), time at maximum concentration (Tmax), 
and area under the curve in the time course of plasma drug concentration from 0 to 8 
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hours after oral administration (AUC0-8hr), are summarized in Table 2. 
 
PK/PD modeling and simulation  
In addition to the plasma concentration of E2110, its occupancy of 5-HT1A 
receptors (Figure 8A) was monitored in four male SD rats over the time course of 8 
hours after a single oral dosing (1 mg/kg). The two-compartment model with first-order 
absorption fitted to the temporal profile of the mean plasma concentration of E2110 was 
then linked to an effect compartment sigmoidal Emax model (Figure 3). The peaking (1.5 
hr) and subsequent decline of 5-HT1A RO by E2110 were somewhat retarded relative to 
the plasma kinetics (Figure 8A), and this slight delay was also indicated by the 
hysteresis curve (Figure 8B). Estimated PD parameters derived from this analysis are 
listed in Table 1. The EC50 value for occupancy of 5-HT1A receptors by E2110 in MPFC 
and DRN were estimated to be 2.87 ng/mL (5.85 nM) and 3.61 ng/mL (7.38 nM), 
respectively. Despite the time lag between the plasma PK and brain RO, these values 
were rather close to those estimated by the direct model, indicating that there were no 
marked hysteresis effects. These PD parameters were utilized to simulate the 5-HT1A 
receptor occupancy versus time profiles in female SD rats (Figure 9). In order to assess 
the validity of this simulation data for predicting RO by E2110, an additional PET study 
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in female rats was performed to determine 5-HT1A RO at 4 hours after oral 
administration of 0.1 mg/kg of E2110, and found that RO values measured by PET were 
in good agreement with calculated data (Figure 9), justifying the use of simulation 
curves to estimate RO in female rats. 
 
Effects of E2110 on micturition reflex in rats 
The effects of E2110 on urinary function were evaluated in rats. The 
micturition intervals in female SD rats were markedly decreased from the basal level by 
intravenous infusion of 8-OH-DPAT (n = 8; Figure 10A) or SCL (n = 8; Figure 10B). 
Oral administration of E2110 at doses of 0.1−0.3 mg/kg in 8-OH-DPAT treatment and 
0.3−1 mg/kg in the SCL model experiment significantly (p < 0.05) prolonged the 
micturition intervals. According to the simulation data (Figure 9), 0.1 mg/kg of E2110 
induced 60−70% RO at 1−2 hours after dosing in 8-OH-DPAT treatment, and 0.3 mg/kg 
of E2110 resulted in 60−80% RO at 0.5−1 hour after dosing in SCL model. From this, it 
can be inferred that at least 60% RO is required for significant effects of E2110 on 
micturition. 
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§ 4 Discussion 
In recent years, PK/PD modeling has been increasingly applied in drug 
discovery and early drug development. Preclinical PK/PD studies may prompt a series 
of important mechanistic studies to investigate the relationship between plasma 
concentrations and resulting effects on a biomarker in later stages of clinical drug 
development. The PK/PD modeling and simulation approaches to preclinical 
pharmacology studies may help to understand the mechanism of action of novel 
compounds and target engagement in preclinical models. The present data have 
demonstrated the utility and robustness of in vivo PET imaging techniques to monitor 
RO in living brains of small animals. Both direct and indirect models yielded a good fit 
to the experimental data and similar EC50 values for the drug under development, E2110, 
validating the use of these methodologies in rats and, potentially, humans. The dose-
dependent effects of E2110 on bladder micturition function were consistently explained 
by the time course of RO induced by the drug, allowing prediction of pharmacologically 
efficacious doses of the drug by clinical PET estimation of RO. 
Based on the results of dose-response PET study conducted at a fixed time 
point after E2110 treatment, 5-HT1A RO was well fitted by a simple Emax model, and the 
free concentration-based EC50 value did not markedly differ between MPFC (0.22 
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ng/mL, 0.45 nM) and DRN (0.16 ng/mL, 0.32 nM). These findings indicate that E2110 
has equal antagonist activities against pre- and post-synaptic 5-HT1A receptors. 
Meanwhile, these free concentration-based EC50 values were approximately 10-fold of 
the Ki value (0.045 nM) calculated from the in vitro binding assay for 5-HT1A receptor. 
The supplemental study indicated that E2110 is a substrate for the BBB drug transporter 
P-glycoprotein in rodents, as the brain-to-plasma concentration ratio (Kp,brain) of E2110 
concentration in mdr1a/1b-knockout mice was ten times higher than that in wild-type 
mice (data not shown). Therefore, the free E2110 concentration in CNS tissues is 
assumed to be one-tenth of its free plasma concentration. On the basis of this 
assumption, the in vivo EC50 values corrected for the difference in free drug 
concentrations between plasma and CNS were estimated to be 0.045 and 0.032 nM in 
MPFC and DRN, respectively, and these values are comparable with in vitro Ki. This 
finding also supports the reliability of PET assays for anesthetized rats to quantify 5-
HT1A RO. Indeed, the use of isoflurane-anesthetized rats for 5-HT1A RO determination 
was justified in a reported [11C]WAY-100635-PET study, which demonstrated that in 
vivo ED50 value for pindolol in the hippocampus (5.6 mg/kg) was rather close to 
hippocampal ED50 value (8.5 mg/kg) estimated by an ex vivo autoradiographic 
measurement for unanesthetized rats [40]. 
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The time course of 5-HT1A RO and plasma PK after a single oral dose of E2110 
(1 mg/kg) offered details of the PK-RO relationships for this drug, and enabled 
simulation of RO in pharmacological models. This effect compartment model well 
described the temporal profiles of 5-HT1A RO, and the EC50 values based on this PK/PD 
modeling were estimated to be 2.87 ng/mL (5.85 nM) and 3.61 ng/mL (7.38 nM) in 
MPFC and DRN, respectively. Hysteresis was observed in a plot of the relationship 
between plasma concentration and 5-HT1A RO, and this lag time is typically observed 
for centrally acting compounds, due to either rate-limiting BBB passage of the 
compounds or slow receptor on/off targets [41]. Although such delay was observed 
between RO and plasma PK of E2110, the EC50 values calculated with the direct and 
effect compartment models were nearly equivalent. Additionally, estimates of the 
equilibration rate constant (ke0) were relatively large, indicating a rapid equilibration 
with the CNS biophase (CNS equilibration t1/2 of 1.4 hours). 
Therefore, hysteresis effects on the target binding of E2110 were minor in the present 
study.  
The present work also demonstrated a profound difference in plasma PK 
profiles of E2110 between male and female SD rats (Table 2). Overt gender differences 
in expression levels of enzymes involved in drug metabolisms were reported in a 
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previous rat study [42], and Chovan et al. documented that substrates of human drug-
metabolizing enzyme cytochrome P450 3A4 (CYP3A4) were mainly metabolized by 
cytochrome P450 3A1/2 and 2C11 in rats [43], and expression levels of these enzymes in 
male rats are known to be higher than in female rats [42]. In addition, the unpublished 
results indicated that E2110 was primarily metabolized by CYP3A4 in human liver 
microsomes. Taking these findings together, it was supposed that the difference in 
plasma PK of E2110 between male and female rats is attributable to gender difference in 
the levels of hepatic cytochromes responsible for metabolism of this drug. Despite these 
effects of gender on PK, 5-HT1A RO in the female rat brain measured by PET was close 
to a value calculated by effect compartment model with ke0 determined in male rats 
(Figure 9), suggesting consistency of the PK-RO relationships between males and 
females. 
These findings in pharmacological tests have provided further support to the 
implication of 5-HT1A receptors in the control of micturition in rats [44, 45]. Numerous rat 
studies have indicated that 5-HT1A receptors have an excitatory physiological role in 
modulating micturition [46]. Both spinal and supraspinal 5-HT1A receptors constitute an 
efficient way to stimulate rat micturition. However, the modulation of the 5-HT1A 
autoreceptor has been proposed to interfere with the micturition reflex [44, 47]. 
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Administration of 8-OH-DPAT was reported to facilitate the voiding reflex, and this 
effect was inhibited by the pretreatment with 5-HT1A receptor antagonists such as WAY-
100635 and NAD-299 [39, 48]. The inhibitory effect of E2110 on the micturition reflex 
observed in the present work could accordingly be attributed to its action on supraspinal 
5-HT1A autoreceptors. In order to correlate the degree of 5-HT1A RO by E2110 yielding 
significant effects in pharmacological tests, I applied simulated temporal profiles of RO 
in DRN enriched with putative autoreceptors after oral doses of E2110 in female SD 
rats (0.03, 0.1, and 0.3 mg/kg). The minimum doses of E2110 exerting overt therapeutic 
effects on the micturition reflex in 8-OH-DPAT and SCL models were 0.1 and 0.3 
mg/kg, respectively. In reference to the simulated RO values, RO at these doses were 
estimated to be around 60% during the micturition monitoring period (at 1−2 hours 
postdose in the 8-OH-DPAT model and 0.5−1 hour postdose in the SCL model), 
demonstrating that RO around 60% or more was necessary for a significant effect on 
bladder function. Thus, for humans, the dosage of a 5-HT1A antagonist would need to be 
determined to achieve this range of RO as a requirement for therapeutic efficacies 
against OAB.  
In summary, these data support that occupancy of central 5-HT1A receptors 
quantified by in vivo PET is a useful biomarker surrogating anti-OAB effects of 5-HT1A 
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receptor antagonists. Although micturition is supposedly regulated by diverse 
neurotransmitter pathways at different levels in the central and peripheral nervous 
systems, the assessment PK-RO relationship using brain PET data would help to 
determine and/or predict effective doses of these candidate drugs in rat models. 
Meanwhile, several factors, including species differences in the protein-unbound 
fraction and the presence or absence of an active metabolite of such a provisional drug, 
should be taken into account in consideration of homology between EC50 values in 
laboratory animals and humans. Species differences in RO and PK-RO relationship 
would be assessable with the aid of comparative PET assays. 
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Chapter. 2 
PET-characterization of [11C]E2110 binding to 5-HT1A receptors 
in rat brain. 
 
§ 1 Introduction 
In the Chapter 1, it have been demonstrated that PET can evaluate the ligand-
target interaction of novel CNS drugs by examination of the competition for specific 
radioligand binding to the target (occupancy studies). Moreover, these tools can provide 
an understanding of the level of receptor occupancy required for pharmacological effect. 
The current results support that molecular imaging approaches with using target-specific 
PET tracers provide the useful information about the correlation between CNS target 
coverage and drug pharmacokinetics.  
If a suitable PET radioligand for the target exists, it would be a very powerful 
translational tool in preclinical research, allowing the measurement of binding 
characteristics of the target (Kd and Bmax) in tissues across species as well as enabling 
assessment of target occupancy during the lead optimization in drug discovery process 
with the unlabeled compound of interest. Furthermore, such a tool can be used to 
correlate target occupancy of a drug candidate with preclinical efficacy and target 
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engagement experiments to support the proof-of-concept (POC) in preclinical stage and 
to estimate the effective dose selection in clinical studies. However, drugs being 
developed at an early stage in the drug discovery often act at totally novel molecular 
sites and, as such, usually there are no existing radioligands acting at these targets. 
Therefore, in the absence of radioligands which directly and specifically label target 
molecules, the use of a radiolabeled version of candidate itself would provide useful 
information about the target-drug interaction.  
In this study, [11C]E2110 was synthesized as the tracer for the central 5-HT1A 
receptor and in vivo binding potential was evaluated. E2110 showed a high affinity for 
5-HT1A receptor in in vitro receptor binding study and it was also shown by in vivo PET 
study with [11C]WAY-100635. Estimated affinity of E2110 to the receptor was 
applicable for imaging of central 5-HT1A receptor as a PET tracer. However, it was 
concerned about the effect of the brain efflux transporter, P-gp, on the distribution of 
E2110 to the brain. Therefore, in this study, elacridar was used as the chemical inhibitor 
for P-gp to improve the brain distribution of [11C]E2110. Under the condition of 
inhibition of P-gp by elacridar, the pharmacological characterization of E2110 was 
conducted by radiolabeling E2110 itself. Binding potential of [11C]E2110 was calculated 
by the transient equilibrium method. Transient equilibrium method has been widely 
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used to investigate the density (Bmax) and affinity (Kd) of labeled compounds [49−51]. In 
experiments in vivo, the ratio of concentration bound to targets (CB) and 
nondisplaceable radioligand in brain (CN) is equal to BP when dCB/dt = 0. This moment 
is called transient equilibrium. To avoid cumbersome arterial blood sampling, CN(t) has 
been approximated with the time-activity curve (TAC) from a reference tissue devoid of 
specific binding sites CREF(t) [52, 53]. The TAC for CB(t) has then been calculated as brain 
tissue radioactivity (CT(t)) minus CREF(t). Although some limitations were noted the use 
of CREF(t) instead of CN(t) [53−56], this simple approach can be useful to determine for the 
evaluation of ligand-target interaction in early preclinical stage.  
Based on the calculated binding potential by transient equilibrium method, 5-
HT1A receptor affinity and density of E2110 was estimated. By using a small-animal 
PET with [11C]E2110, ligand-target interaction was directly evaluate and the utility of 
this methodology in the early drug discovery stage was discussed 
 
§ 2 Materials and Methods 
Reagents 
E2110 was synthesized at Eisai Co., Ltd. (Japan). Elacridar (GF120918) [N-(4-
(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl)phenyl)-9,10-dihydro-5-
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methoxy-9-oxo-4-acridine carboxamide] was purchased from Toronto Research 
Chemicals (Toronto, Ontario , Canada). 
 
Animals 
The research protocols of the present work were approved by the Animal 
Ethics Committee of the National Institute of Radiological Sciences and were 
performed in accordance with the Principles of Laboratory Animal Care (NIH 
publication No. 85-23, revised 1985). 
Male SD rats were purchased from Japan SLC (Hamamatsu, Japan). All rats were kept 
in animal rooms maintained at 20−26°C and illuminated from 7 am to 7 pm daily, with 
ad libitum access to food and water. 
 
Synthesis of radiotracers 
[11C]CH3I was introduced to a solution of pre-E2110-OH (1.2 mg, 2.5 μmol) 
and NaOH (0.5 mol/L solution, 6 μL, 3 μmol) in DMF (300 μL) at 0 °C. The reaction 
mixture was heated at 40 °C for 3 min and purified by HPLC (Capcell Pak C18, S-5 μm, 
10 mm ID ×250 mm, Shiseido Co., Ltd., Tokyo, Japan) using the mobile phase of 
Acetonitrile/H2O/Tetraethylammonium (TEA) (5/5/0.01, v/v/v) at a flow rate of 6.0 
44 
 
mL/min to give 1.05 GBq of [11C]E2110. The tR of [11C]E2110 was 7.3 min for 
purification and 6.4 min for analysis on HPLC (YMC Pack Pro C18, S-5 μm, 4.6 mm 
ID ×150 mm, YMC Co., Ltd., Kyoto, Japan) using the mobile phase of Acetonitrile 
/H2O/TEA (5/5/0.01, v/v/v) at a flow rate of 1.5 mL/min. The synthesis time from EOB, 
28.1 min; radiochemical yield decay-corrected), 9.2 % based on [11C]CO2; 
radiochemical purity, > 99%; specific activity at EOS, 213 GBq/μmol (n = 7). 
 
Elacridar treatment and PET scan 
All PET scans for rats were performed with a small animal-dedicated 
microPET FOCUS 220 system (Siemens Medical Solutions USA, Knoxville, TN, USA), 
which yields a 25.8 cm (transaxial) × 7.6 cm (axial) field of view (FOV) and a spatial 
resolution of 1.3 mm full width at half maximum at the center of FOV [33]. A 20 min 
transmission scan for attenuation correction was performed using a spiraling 68Ge−68Ga 
point source. Subsequently, list-mode scans were carried out for 150 min. All list-mode 
data were sorted and Fourier rebinned into two-dimensional sinograms (frames: 4 × 1, 8 
× 2, and 26 × 5 min). Images were thereafter reconstructed using two-dimensional 
filtered back-projection with a 0.5 mm Hanning filter.  
Elacridar, 3 mg/kg, was administered intravenously 30 minutes before tracer 
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injection. [11C]E2110 was injected via the tail vein as a single bolus at the start of 
emission scanning. The injected dose of the radiotracer was 126.5 ± 10.9 MBq/rat 
(mean ± SD). For the determination of densities and affinities, the tracer containing 
various amounts of cold mass (0, 10, 30, 60, and 600 nmol) for 5 different PET scans 
was used. In experiments, scans for the same individual receiving E2110 were 
conducted more than 1 week apart. 
 
PET data analysis 
Anatomical regions of interest (ROIs) were placed on the medial prefrontal 
cortex (MPFC), hippocampus (HIP) and cerebellum (CER) using PMOD® image 
software (PMOD Group, Zurich, Switzerland) with reference to the MRI template. 
Time-radioactivity curve of each region was expressed in %ID/mL, normalized to the 
injected radioactivity, and plotted against time. 
 
In vivo Scatchard analysis 
The data were obtained at systematically varied ligand concentrations and 
analyzed by means of Scatchard plots [53, 57, 58]. The binding parameters for [11C]E2110 
were obtained by performing 5 separate scans and various specific radioactivities on one 
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animal. For the low specific-radioactivity conditions, 10−600 nmol of cold E2110 was 
added to the tracer. The hyperbolic saturation curve of tracer binding was defined as: 
(6) 
In case of two-site binding, the hyperbolic equation (Equation 6) is modified to the 
following equation: 
(7) 
where B is the concentration of bound ligand (pmol/mL), F is the concentration of free 
ligand (pmol/mL), Bmax is the total receptor density (pmol/mL), and Kd is the 
dissociation constant (nM). The total radioligand concentration in the cerebellum 
(reference region) which was used as an estimate of F, since the density of 5-HT1A 
receptors is negligible in cerebellum. Specific binding (B) was defined as the difference 
in radioactivity between specific binding regions (ROIs) and reference region. Transient 
equilibrium is established when the radioactivity in each ROIs is maximal [53,57] and at 
this timepoint, the derivative for specific binding was 0 (dCb/dt =0). The equilibrium 
time was defined by fitting the curve for B to a 3-exponential equation [59]. The Bmax and 
Kd values were calculated by nonlinear hyperbolic analysis with the equation one-site 
model (Equation 6) or two-site model (Equation 7) using the fitting software Prism 
(GraphPad Software, San Diego, CA, USA). Also, the regressed hyperbolic curve (x is 
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F and y is B) was transformed to create the Scatchard plot graph (x is B and y is B/F). 
 
§ 3 Results 
Effect of Elacridar on [11C]E2110 brain distribution 
The representative PET images in brain with or without elacridar treatment are 
shown in Figure 11. Pre-treatment of elacridar (3 mg/kg, IV) dramatically improved the 
brain distribution of [11C]E2110. Also, high accumulation of [11C]E2110 was observed 
in a pattern consistent with the known central 5-HT1A receptor distribution [60]. 
Representative time-radioactivity curves of [11C]E2110 in each condition are also shown 
in Figure 11. 
 
In vivo Scatchard analysis by [11C]E2110 PET with multidose ligand treatment 
With increasing doses of unlabeled E2110, the radioactivity showed a stepwise 
attenuation in all regions. The dose-dependent reduction of [11C]E2110 binding to 5-
HT1A receptor in the multidose ligand assays was observed by alterations to the time 
curve of specific binding in MPFC and HIP. The transient equilibrium of specific 
binding was reached at 70−90 min in the MPFC, 55−75 min in the HIP. 
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Figure 12 shows the Scatchard plots for the MPFC and HIP. Equilibrium values 
for specific binding (B) and free [11C]E2110 concentration (F) were obtained at the 
point dCB/dt was 0. Based on the shapes of Scatchard plot of [11C]E2110, two-site 
binding model was used to fitting. The in vivo Bmax and Kd values of [11C]E2110 in two 
ROIs are summarized in Table 3. 
 
§ 4 Discussion 
The BBB prevents hydrophilic compounds from entering the CNS and is thus a 
major hurdle in designing drugs directed at the brain. It has been estimated that 98% of 
small-molecule compounds do not cross the BBB in sufficient amounts [61], and a lack 
of adequate brain exposure has contributed to a significant number of failures in the 
development of CNS drugs [62]. In CNS drug research, biodistribution study with 
radiolabeled compound can be useful in early preclinical stage to assess if the 
compound crosses the BBB and to evaluate in vivo affinity of the compound to the 
target. However, there are some difficulties in the case the compound might be a 
substrate of active transport systems in the BBB. The supplemental research indicated 
that E2110 could be a substrate of P-gp. P-gp is an adenosine triphosphate-driven efflux 
pump expressed at BBB. Many structurally unrelated drugs, including various 
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anticancer drugs, antidepressants, steroids, and HIV protease inhibitors, are substrate of 
P-gp and are extruded from the brain by this efflux pump [63, 64]. For the PET tracers, it is 
suggested that non-substrate for brain efflux transporters (e.g., P-gp and BCRP) are one 
of the criteria to be met ideally by radiotracers [65]. Based on the results of this study, in 
rats, the free E2110 concentration in brain tissues is assumed to be one-tenth of its free 
plasma concentration. In terms of the pharmacological property, E2110 showed the high 
binding affinity to the central 5-HT1A receptors both in vitro receptor binding assay and 
in vivo PET RO study with [11C]WAY-100635. For the estimation of in vivo affinity to 
the target molecules and investigation of the correlation to the in vitro assay results, 
receptor occupancy study with specific binding tracer is useful because this kind of 
study could be conduct at pharmacological active dose, and even if the test compounds 
might be a substrate of efflux pump in the CNS, the pharmacological efficacy would be 
evaluated by increasing a doses. On the other hand, in the case the evaluation of in vivo 
target affinity of compounds by radiolabeled version of compound, effect of the efflux 
pump at BBB would be significant on the brain distribution of compound.  
In animals, it has been reported that some inhibitors for these transporters are 
available to increase brain distribution [64, 66−68]. Elacridar (GF 120918) is widely used as 
P-gp and BCRP inhibitor [69, 70]. In in vitro, elacridar inhibited P-gp mediated transport 
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of the P-gp substrate [3H]paclitaxel in a P-gp-overexpressing cell line with inhibition 
constants (Ki) of 109 nM [71]. Preclinical studies have shown that elacridar potently 
inhibit P-gp function at the BBB as reflected by increased brain uptake of P-gp 
substrates, without displaying cytochrome P450-mediated pharmacokinetic interactions 
[68, 72, 73]. It has also been shown that elacridar is increasing brain distribution of 
verapamil and loperamide (ED50 = 1.2−2.4 mg/kg) with no effect on metabolism and 
plasma protein binding [67, 72]. Elacridar also significantly increased brain distribution of 
several tyrosine kinase inhibitors (TKIs) [74−79]. 
In the baseline experiments (i.e., before inhibition), the radioactivity level of 
[11C]E2110 in ROIs were rather low (Figure 11), which suggested that E2110 is 
efficiently kept out of brain by P-gp-mediated efflux. However, the brain distribution of 
[11C]E2110 was dramatically improved by 3 mg/kg of elacridar pretreatment. In this 
condition, the specific binding to the 5-HT1A receptor could be assessed by multidose 
ligand assays with the Scatchard analysis. In this study, B/F was estimated based on the 
equilibrium analysis in rat brain regions. 
[11C]E2110 was highly accumulated in ROIs and negligible in reference tissue. 
The obtained Scatchard plot indicated two-site binding model would be suitable for 
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fitting. Therefore, as shown in Table 3, two different types of [11C]E2110 binding 
parameters are estimated in each brain regions.  
As shown in Table 3, Kd and Bmax values in each region were calculated from a 
regression line with good correlation (R2 = 0.82−0.87). In MPFC, the estimated Kd 
value of high-affinity sites for 5-HT1A receptor was 0.5 nM. This value was about 10-
fold larger than the Ki value in in vitro receptor binding assay. Possible consideration for 
this gap between in vitro and in vivo is the difference of actual ligand concentration in in 
vivo this analysis. In in vivo RO study, Kd value was estimated by the concentration in 
cerebellum as free ligand concentration. However, this value includes the 
nonspecifically binding fraction of E2110 to the tissue. Therefore, the use of the total 
cerebellar activity as an estimate of the free ligand concentration leads to an 
overestimation of Kd value. In the Capter.1, the plasma protein binding of E2110 was 
calculated to be 94%. This result indicates E2110 would be nonspecifically bound to 
brain tissue and about one-tenth of E2110 concentration in reference tissue would be 
exist as free (unbound) form. On the basis of this assumption, the Kd value obtained 
from in vivo Scatchard analysis is almost equivalent that from in vitro receptor binding 
assay.  
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Elacridar pretreatment could modify the activity of P-gp at BBB, but a previous 
animal imaging study found some evidence for a non-uniform distribution of P-gp in rat 
brain. Laćan et al. quantified P-gp expression by Western blot analysis and found two 
times higher P-gp levels in cerebellum as compared to other brain regions (e.g. 
hippocampus, frontal cortex) of rats [80]. This report suggests that the in vivo binding 
study with P-gp substrate tracer have the potential to overestimate the affinity because 
of the regional heterogeneity of P-gp in brain. In this case, since cerebellum was used as 
reference tissue, it may be considered about two-fold difference would include in the 
estimation of Kd values. Also in HIP, Scatchard analysis suggested E2110 bound to the 
receptor with high affinity (Kd = 1.1 nM). However, the Kd value in HIP was about two-
fold higher than that in MPFC (0.5 nM). These regional differences of receptor binding 
affinity were also suggested in receptor occupancy study with [11C]WAY-100635. Based 
on the results of additional analysis of E2110 RO data, the EC50 value of E2110 in HIP 
was calculated to be 16.0 nM (Figure 13). These data indicated that E2110 may have 
different affinity to same receptor in different brain regions. Further study would be 
required to explain this unique behavior of E2110 to the receptors 
In present study, in vivo Scatchard analysis was performed for the 
determination of Bmax and Kd of E2110 using PET. The equilibrium analysis with 
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validated reference region [60,81,82] was useful to in vivo measurement for pharmacologic 
indices of this radioligand. Also, [11C]E2110 PET data combined with elacridar 
administration demonstrated that P-gp inhibitor can improve brain uptake and this 
approach would be a useful even if the radiolabeled compound is supposed to be a P-gp 
substrate. Non-uniform distribution of P-gp in brain was suggested that regional 
activities may need to be factored into PET kinetics of tracers that are substrate for P-gp 
to enable accurate quantification of receptor densities in in vivo. In many cases, lead 
compounds with desirable pharmacological activity may have undesirable properties 
related to pharmacokinetics in early preclinical stage. Present study demonstrated that 
PET imaging technique provides the opportunity to obtain proof of mechanism (POM) 
of the compound so that later studies can be performed with the confidence that the 
compound is acting as expected. In addition, the investigation of in vitro-in vivo 
relationship in pharmacological activity would help the optimal estimation of effective 
dose in human.  
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Conclusion 
In 2004, the Food and Drug Administration (FDA) released an article titled: 
“Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New 
Medical Products.”[83] In this article, the FDA defines biomarkers as “quantitative 
measures of biological effects that provide informative links between mechanism of 
action and clinical effectiveness” and surrogate endpoint as “quantitative measures that 
can predict effectiveness.” The purpose of this thesis is to evaluate the utility of 
quantitative molecular imaging using small-animal PET for CNS drug discovery and 
development as a biomarker. The interaction between central 5-HT1A receptor and 
E2110 which is a novel antagonist of this receptor was investigated by several 
methodologies including receptor occupancy, PK/PD modeling, and in vivo Scatchard 
analysis. Obtained biomarker response was used to predict the pharmacological efficacy 
in animal models and endpoint in preclinical stage was discussed. The primary 
observations in the present study are summarized as follows: 
1) The plasma concentration-dependent occupancy of central 5-HT1A receptors by 
E2110 was demonstrated by in vivo PET with specific tracer [11C]WAY-100635. The 
PET study indicated that the occupancy data would be a useful biomarker 
surrogating anti-OAB effects of novel 5-HT1A receptor antagonists. Also, the 
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assessment PK-RO relationship using brain PET data would help to determine 
and/or predict effective doses of E2110 in animal models.  
2) Binding parameters (Kd, Bmax) of E2110 for rat central 5-HT1A receptors were 
determined by using multidose ligand approach with radiolabeled E2110 
([11C]E2110). 3 mg/kg of elacridar treatment improved the brain uptake of E2110 
and successfully conducted the in vivo Scatchard analysis. The binding 
characteristics will aid the understanding the in vitro-in vivo correlation of 
pharmacological activity of compound and exposure-efficacy relationship in animal 
models.  
Throughout this research, the pharmacological activity of E2110 as a central 5-
HT1A receptor antagonist was well characterized in vitro and in vivo. As the results, the 
in vitro 5-HT1A receptor affinity (Ki) of E2110 in rat was close to the parameter that was 
estimated from PET receptor occupancy and Scatchard analysis in vivo. The relationship 
between pharmacological efficacy and 5-HT1A receptor occupancy was also assessed 
and was clarified as the target 5-HT1A receptor occupancy over 60% in the animal 
model of overactive bladder. With respect to the requirement of receptor occupancy for 
pharmacological efficacy of CNS targeted drugs, it has been reported that 60−80% of 
occupancy would be required for GPCR antagonists [84]. However, these occupancy 
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requirements still have to be discussed in terms of time point of occupancy assessment, 
and clinical relevancy of animal models and contribution of 5-HT1A receptor to the 
control of bladder function. In terms of the side effects that are related to 5-HT1A 
receptor blockade, Rabiner et al. evaluated the central 5-HT1A receptor occupancy by 
novel full antagonist, DU125530 [36]. Based on the report, DU125530 displayed a dose-
dependent occupancy of the 5-HT1A receptor in the human brain, reaching up to 72% 
with minimal side effects. These reports indicate E2110 would show the efficacy with 
no serious side effects by optimization of therapeutic dose based on the occupancy 
information. Therefore, PK/PD relationship established in this study would be useful in 
the translational approach to estimate the E2110 dose required for anti-OAB effect in 
further clinical trials. Also, these preclinical findings suggest that receptor occupancy is 
a meaningful PD biomarker for understanding the drug-receptor interaction that 
underlies a pharmacological effect and is useful for predicting the effective and safe 
dose ranges given drug candidate. E2110 have high affinity to 5-HT1A receptor and have 
shown pharmacological efficacy in animal model, but [11C]E2110 at a tracer level could 
not show the distribution to the brain. This result demonstrated that the contribution of 
P-gp efflux to brain penetration of E2110 was critical at a tracer dose, while a 
significant amount of E2110 could enter in brain at effective dose. In this study, the 
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brain penetration of [11C]E2110 was improved by pre-treatment of elacridar and in vivo 
binding parameters were successfully estimated by using small-animal PET. 
In recent years, imaging techniques are widely applied in drug discovery and 
development for evaluation of CNS drug disposition and for validation of disease 
biomarkers and tracers for novel targets [85−87]. Imaging at the molecular level provides a 
direct measure of mechanism of action, offering a more predictive measure of drug 
activity through the use of targeted image-based predictive biomarkers. As a result of 
these efforts, imaging is now being used to drive go/no-go decisions in early discovery, 
and there is a significant focus on developing and validating image-based biomarkers 
that are intended to be applicable for use in clinical trials. The results of this research 
also support the utility of using these techniques in the pharmacological characterization 
of novel drugs and propose the importance of information about pharmacokinetic 
properties. Translational PET research associated with PK/PD modeling and simulation 
in drug discovery and early clinical development would provide a sound basis for 
support of appropriate selection of candidate compound in preclinical stage and dose 
selection and optimization of dose regimens for early studies conducted in patients.  
CNS disorders have a complex etiology and very few animal models are 
available to predict clinical efficacy. In this thesis, the contribution of target occupancy 
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to the pharmacological efficacy was well characterized by PK/PD analysis using PET. 
This approach would also be used to the other CNS disorders if target molecule (e.g., 
receptor, transporter, enzyme) relevant to disease status. To avoid wasting time and 
resources, more reasonable and plausible approach would be required for future drug 
discovery. This imaging and modeling frameworks to develop a preclinical translation 
model could be applicable to other CNS drug discovery and development and contribute 
to improve productivity of pharmaceutical industries.  
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Figure 1 Serotonergic pathways controlling bladder functions in the rat. Descending 
projections from the brainstem raphe neurons to the spinal cord activate segmental 
interneurons that provide an inhibitory input to the parasympathetic preganglionic 
neurons (PGN) innervating the bladder. Blockade of inhibitory 5-HT1A autoreceptors in 
the raphe neurons enhances raphe neuron firing and, increases the release of 5-HT in the 
spinal cord. 5-HT activates excitatory 5-HT2C receptors on inhibitory interneurons, 
which then suppresses PGN firing [88].  
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Chemical name:  
1-{1-[2-(7-Methoxy-2,2-dimethyl-4-oxochroman-8-yl)ethyl]piperidin-4-yl}-N-methyl-
1H-indole-6-carboxamide fumarate 
Molecular formula: C29H35N3O4 · C4H4O4 (C33H39N3O8) 
Molecular weight: 605.68 (489.62 as free form) 
 
 
Figure 2 Chemical structure of E2110 
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Figure 3 Schematic illustration of a model for description of E2110 PK/PD. Cp, E2110 
concentration in the central compartment; Ce, E2110 concentration in the effect 
compartment; ka, absorption rate constant; ke0, equilibrium rate constant; V1, central 
volume of distribution; V2, peripheral volume of distribution 
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Figure 4 In vitro inhibition profiles of E2110 and WAY-100635 on 5-HT1A receptors. 
Inhibition of specific [3H]MPPF binding in rat hippocampal membrane homogenates 
was measured at various concentrations of E2110 (●) and WAY-100635 (○) 
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Figure 5 Representative PET images illustrating distribution of [11C]WAY-100635 in rat 
brains at baseline and after oral administration of E2110. PET images were generated by 
averaging dynamic data at 60−90 min after intravenous radiotracer injection, and were 
overlaid on the MRI template shown in the far left column. Coronal brain sections 
shown here were obtained at 1.0 mm (top row), -7.8 mm (middle row) and -12.5 mm 
(bottom row) from the bregma. ROIs (dotted lines) were defined on the MPFC (top 
row), DRN (middle row) and cerebellum (CER; bottom row). The radiotracer retention 
was presented as a percentage of the injected dose per unit tissue volume (%ID/mL) 
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Figure 6 Relationship between rat 5-HT1A RO (MPFC: ●, DRN: ◇) and E2110 plasma 
concentration. 5-HT1A RO was determined at 4 hours after oral administration of E2110 
at a dose ranging from 0.3 to 10 mg/kg. Symbols represent individual data from all dose 
levels (n = 4/dose level). 
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Figure 7 Plasma PK profile of E2110 after oral administration to rats. Symbols denote 
observed plasma concentrations (mean ± S.E.M, n = 4/time point) in male (●) and 
female SD rats (○). Lines represent fitting of a two-compartment PK model with first-
order absorption to the experimental data 
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Figure 8 Time course data of rat 5-HT1A RO in MPFC (●) and DRN (◇), and plasma 
E2110 concentration (thick dashed line) (A), and plot of RO against plasma E2110 
concentration at individual time points (B). 5-HT1A RO was determined at assigned time 
points after oral administration of E2110 at a dose of 1 mg/kg. Symbols represent mean 
± S.E.M at indicated time points (n = 4/time point). Lines indicate the predicted 
occupancy versus plasma concentration in MPFC (solid line) and DRN (dashed line) 
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Figure 9 Effect compartment model estimation of 5-HT1A RO in DRN after oral 
administration of E2110 at doses of 0.03, 0.1 and 0.3 mg/kg to female rats. Solid circle 
and error bars represent mean RO ± S.E.M measured by PET scans in female rats (n = 
3). 
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Figure 10 Effects of E2110 on micturition interval in 8-OH-DPAT-infused (A) and SCL 
(B) rats. Values are expressed as mean ± S.E.M. of eight rats in 8-OH-DPAT-infused and 
SCL models; * P < 0.05 versus vehicle (Dunnett’s multiple test) 
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Figure 11 Representative PET images illustrating distribution of [11C]E2110 and time-
activity curve in rat brains at baseline (A) and 3 mg/kg of elacridar treatment conditions 
(B). PET images were generated by averaging dynamic data at 0−90 min after 
intravenous radiotracer injection, and were overlaid on the MRI template. ROIs were 
defined on the MPFC, HIP and CER (as reference region). The radiotracer retention was 
presented as a percentage of the injected dose per unit tissue volume (%ID/mL) 
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Figure 12 Scatchard plot of [11C]E2110 specific binding in MPFC (●) and HIP (□). The 
continuous and broken lines show the regression lines for each region by two-site 
binding model. 
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Figure 13 Relationship between rat 5-HT1A RO (MPFC: ●, HIP: □) and E2110 plasma 
concentration. The continuous and broken lines show the regression lines for each 
region. Symbols represent individual data from all dose levels (see Chapter 1). 
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Table 1 In vitro pharmacological profile and in vivo PD parameter estimates for E2110. 
 In vitro    In vivo 
 5-HT1A 
receptor  
affinity 
  
ROI 
5-HT1A RO 
 
 
 Dose-response study  
Time-course 
study 
Ki 
(nM) 0.045 
EC50 
(nM) 
MPFC 7.51 (0.45*)  5.85 (0.35*) 
 DRN 5.40 (0.32*)  7.38 (0.44*) 
*: free concentration based value. 
 
 
 
Table 2 PK parameter estimates after oral administration of E2110 to male and female 
SD rats. 
Pharmacokinetic parameters  Male  Female  
t1/2 (hr)  1.5  2.6  
Cmax (μg/mL)  48.1  125.7  
Tmax (hr)  0.5  1  
AUC0-8hr (μg•hr/mL)  71.8  487.9  
 
 
Table 3 In vivo measurements of Kd, Bmax, and BP by Scatchard analysis in rat brain. 
Region 
 High Affinity  Low Affinity  
R2‡ 
 Kd1  Bmax1  BP1†  Kd2  Bmax2 BP2†  
MPFC  0.5  15.1  30.3  101.4  87.8 0.9  0.82 
HIP  1.1  13.1  11.9  51.5  42.1 0.8  0.87 
Unit: Kd (nM), Bmax (pmol/mL) 
†: BP = Bmax/Kd 
‡: Coefficient of determination. 
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